NetApp Advance Offers Organizations Next Level Hybrid Cloud Flexibility and Efficiency
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the availability of NetApp Advance, a new portfolio of storage programs and guarantees to help customers cost-effectively future proof on-premises environments.
NetApp Advance evolves the storage lifecycle, allowing organizations the possibility to avoid complex, costly, and time-consuming refresh cycles by enabling ongoing, non-disruptive hardware upgrades – and ensures efficient, secure and sustainable storage with new guarantees offered to meet the needs of organizations today.
With simplified storage ownership and management, NetApp Advance can help to eliminate complex, time-consuming, and costly upgrade cycles while staying current with technology innovations. Organizations can choose on-premises or cloud storage options to future-proof environments to scale securely, seamlessly, and non-disruptively as they grow. Advance also brings sustainability and efficiency best practices and capabilities that continually improve energy efficiency and operational performance to reduce carbon footprint.
“NetApp Advance brings peace of mind to forward looking organizations in need of storage solutions that can adapt and scale as their business changes and grows,” said Sandeep Singh, Senior Vice President, Enterprise Storage at NetApp. “With NetApp Advance, we’re offering customers the confidence that their storage investment today will provide the flexibility to meet their hybrid cloud needs for the future.”
New benefits of NetApp Advance include:
- Reducing the cost, complexity, and disruption of tech refreshes by buying once and evolving continuously.
- Greatly reducing the risk previously associated with the journey to hybrid cloud with the flexibility to easily scale out to the cloud if or when business demands it.
Part of NetApp Advance, the new NetApp Storage Lifecycle Program offers:
- No additional cost non-disruptive upgrades to the latest storage controller technology every three, four, or five years
- Option to upgrade controllers at only incremental cost prior to three-year renewal.
- Optional capacity refresh allowing customers to replace lower capacity drives as part of a storage refresh, so customers never have to buy the same capacity twice and can achieve a more efficient & sustainable data center footprint.
- Remotely managed software updates including non-disruptive ONTAP software upgrades packed with new capabilities and enhancements.
- Premier-level support services, with Active IQ and Cloud Insights that enable full-stack visibility and AIOps to streamline observability of the infrastructure beyond the storage layer in a single interface to quickly pinpoint issues and simplify troubleshooting. While ONTAP Essentials provides detailed overviews of ONTAP inventories, workloads, and data protection.
Additionally, the NetApp Storage Lifecycle Program introduces the NetApp Cloud Advantage Program, which allows organizations to trade in controllers for full credit toward their choice of NetApp cloud solutions to enable easy scale out to the cloud in order to meet changing business demands – and two new guarantees to benefit organizations in need of agile and efficient storage consumption options and models.
NetApp’s 4:1 SAN Storage Efficiency Guarantee offers that if workload efficiency goals are not met, NetApp will rectify this at no cost to the customer. Available for all AFF all-flash systems.*
NetApp will also introduce a new Sustainability SLA for NetApp Keystone customers. Keystone comes standard with 99.999 percent data availability.* Now Keystone will provide a standard Watts/TB for each SLA-based performance level, with service credits available if those targets are not met. This new SLA is planned for availability in the first calendar quarter of 2023 and specific terms and conditions will apply.
With NetApp BlueXP, customers will soon have access to a new, industry-first Sustainability Dashboard – available for preview in the first quarter of NetApp’s fiscal year 2024. This dashboard provides a holistic view of an organization’s IT environment with real data measuring power, energy and heat usage to deliver a sustainability scorecard. By offering actionable insights with AIOps to improve their overall score and reduce their storage carbon footprint, organizations can simply and easily monitor and achieve their IT sustainability goals.
“As a NetApp partner, EVT is helping our joint customers optimize their IT environment and accelerate their journey to the cloud,” said Scott Gelb, Solutions Architect at Enterprise Vision Technologies. “With NetApp’s announcement of NetApp Advance, we’re now perfectly positioned to help customers do just that by providing a flexible path to non-disruptive upgrades of their on-premises hardware systems, or to right-size their hybrid cloud environments as they scale out to any cloud with credits toward their choice of NetApp cloud solutions. By future-proofing their investment with Advance, we can limit risk and offer infrastructure agility as their business evolves.”
NetApp Advance is available today. Also announced today, the upcoming availability of NetApp AFF C-Series, a new family of capacity flash storage options that deliver lower cost all-flash storage, and NetApp AFF A150, a new entry-level storage system in the AFF A-Series family of all-flash systems.
*Terms and conditions will apply.
Additional Resources
- NetApp Advance
- Blog: Fresh NetApp Innovation to Revolutionize Your Data Center
- Blog: Future-Proof Your Storage Investments with NetApp Advance
- Blog: If You Can’t Measure Sustainability, You Can’t Manage It
- Press Release: NetApp Announces New Line of High-Capacity, Low-Cost Flash Storage for the Modern Data Center
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005469/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
